Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Randomized, Open-Label Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01533753
• Other study ID #: CO11813
• Secondary ID: 2011-0492A534260
• Status: Terminated
• Phase: Phase 2
• Start date: February 2012
• Est. completion date: May 2014

Study information

• Verified date: September 2014
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the change in quality of life over a 6 month period between gabapentin and venlafaxine in men with prostate cancer treated for hot flashes related to androgen deprivation therapy.

Description:

60 evaluable patients with prostate cancer currently receiving androgen ablation therapy or who have had an orchiectomy will be enrolled in this study. All patients will be randomized 1:1 (30 patients per treatment arm) to either receive gabapentin or venlafaxine. Treatment duration will be a total of 6 months. During those 6 months, study staff will evaluate frequency and intensity of hot flashes using hot flash score from hot flash diary every 28 days. Patients will also record side effects associated with either gabapentin or venlafaxine on their medication diaries. Study staff will record the severity of all adverse events reported. Patients will also complete the quality of life Functional Assessment of Cancer Therapy-Prostate (FACT-P) form at baseline, cycle 3, and cycle 6/off study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: May 2014
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men 18 years or older with histologically proven adenocarcinoma of the prostate

• Prior or current androgen deprivation for at least 6 months prior to study entry with either bilateral orchiectomy or being maintained on a stable dose of LHRH (luteinizing hormone-releasing hormone) agonist or antagonist

• Hot flash frequency of an average of 2 or more per day (average of 14 hot flash episodes per week)

Exclusion Criteria:

• cannot currently be taking serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) or monoamine oxidase inhibitors (MAOIs)

• cannot have uncontrolled hypertension

• cannot have history of past or current of epilepsy, epilepsy syndrome or other seizure disorder

• cannot have psychiatric history of mania, hypomania, bipolar disorder or anorexia nervosa

• cannot be receiving concurrent treatment with amy medications or herbal products being used with the express purpose of treating hot flashes.

Related Conditions & MeSH terms

• Hot Flashes
• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Gabapentin
Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
• Venlafaxine
Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.

Locations

Country	Name	City	State
United States	University of Wisconsin Hospital and Clinics (Carbone Cancer Center)	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Quality of Life	We will measure the absolute change in the Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score, between gabapentin and venlafaxine in men with prostate cancer treated for hot flashes related to androgen deprivation therapy	observed over a 6 month treatment period
Secondary	Compare Toxicity Rates Between the Gabapentin and Venlafaxine Treatment Groups	Toxicity rates will be compared between the two groups	over a 6 month treatment period
Secondary	Assess Changes in the Hot Flash Scores for the Two Arms	Assess percentage changes in the hot flash score from baseline to cycle 6 between gabapentin and venlafaxine in men with prostate cancer treated with for hot flashes related to androgen deprivation therapy	6 month treatment period
Secondary	Assess Changes in Quality of Life Using the Hot Flash Related Daily Interference Scale (HFRDIS)	Assess percent change in quality of life from baseline to cycle 6, as measured by the Hot Flash Related Daily Interference Scale (HFRDIS) total score, between gabapentin and venlafaxine in men with prostate cancer treated for hot flashes related to androgen deprivation therapy.	over the 6 month treatment period

External Links

•   University of Wisconsin Carbone Cancer Center